Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.3%. By the end of trading, Bristol-Myers Squibb Company fell $0.48 (-1.1%) to $44.51 on light volume. Throughout the day, 6,436,039 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10,923,900 shares. The stock ranged in price between $44.51-$45.44 after having opened the day at $45.18 as compared to the previous trading day's close of $44.99. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 35.8%, Verastem ( VSTM), down 11.1%, Regulus Therapeutics ( RGLS), down 9.6% and Skystar Bio-Pharmaceutical Company ( SKBI), down 6.0%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $74.2 billion and is part of the health care sector. Shares are up 38.0% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Synthetic Biologics ( SYN), up 9.8%, Insmed ( INSM), up 9.4%, IntelliPharmaCeutics International ( IPCI), up 8.8% and Star Scientific ( STSI), up 8.1% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists